TY - JOUR
T1 - EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers
AU - Fukuyoshi, Y.
AU - Inoue, H.
AU - Kita, Y.
AU - Utsunomiya, T.
AU - Ishida, T.
AU - Mori, M.
N1 - Funding Information:
We thank T Shimooka, K Ogata, N Kasagi, and Y Nakagawa for their excellent technical assistance. This study was supported by Grant-in-Aid for Scientific Research (S) (17109013), Grant-in-Aid for Scientific Research (B) (18390367), and Grant-in-Aid for Exploratory Research (18659384) from the Japan Society for the Promotion of Science and Core Research for Evolutional Science and Technology of Japan Science and Technology.
PY - 2008/5/6
Y1 - 2008/5/6
N2 - Fusion genes have been identified as chromosomal rearrangements in certain cancers, such as leukaemia, lymphoma, and sarcoma. The EML4-ALK (EML4: echinoderm microtubule-associated-protein-like 4; ALK: anaplastic lymphoma kinase) fusion gene has been identified as an oncogene in non-small-cell lung cancer (NSCLC). This study examined the presence of this fusion transcript in gastrointestinal and breast cancers. We evaluated the expression of the EML4-ALK transcript in 104 lung cancer cases and in 645 gastrointestinal and breast cancer samples. Only one of the lung cancer samples tested positive for the EML4-ALK fusion transcript, whereas none were detected in 555 gastrointestinal and 90 breast cancer cases. Our data suggest that the EML4-ALK fusion transcript is not present in gastrointestinal or breast cancers and is specific to NSCLC.
AB - Fusion genes have been identified as chromosomal rearrangements in certain cancers, such as leukaemia, lymphoma, and sarcoma. The EML4-ALK (EML4: echinoderm microtubule-associated-protein-like 4; ALK: anaplastic lymphoma kinase) fusion gene has been identified as an oncogene in non-small-cell lung cancer (NSCLC). This study examined the presence of this fusion transcript in gastrointestinal and breast cancers. We evaluated the expression of the EML4-ALK transcript in 104 lung cancer cases and in 645 gastrointestinal and breast cancer samples. Only one of the lung cancer samples tested positive for the EML4-ALK fusion transcript, whereas none were detected in 555 gastrointestinal and 90 breast cancer cases. Our data suggest that the EML4-ALK fusion transcript is not present in gastrointestinal or breast cancers and is specific to NSCLC.
UR - http://www.scopus.com/inward/record.url?scp=43249099270&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=43249099270&partnerID=8YFLogxK
U2 - 10.1038/sj.bjc.6604341
DO - 10.1038/sj.bjc.6604341
M3 - Article
C2 - 18414414
AN - SCOPUS:43249099270
VL - 98
SP - 1536
EP - 1539
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 9
ER -
